Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The incidence of malaria cases continued to drop dramatically in rural and remote Myanmar villages after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services. Adding the health services to malaria control benefitted the villagers access to health and improved malaria services – paving the way for malaria elimination.

Local people on an elephant

Villages where trained community health workers (CHWs) provided malaria diagnosis and treatment experienced a 70% decline in P. falciparum and a 64% drop in P. vivax malaria incidence for each year of operation, the scientists say in a study published in BMC Medicine.

But as malaria fell so did the number of people being screened. When community health workers began offering a broader package of health services – including for tuberculosis (TB), respiratory tract infections, malnutrition and diarrhoea, while continuing to screen for malaria – health improved and so did malaria control.

“To maintain effective malaria control in hard to reach areas village health workers were trained both to screen and treat malaria and to handle other common health care needs,” said study author Oxford Prof Frank Smithuis, Director of the Myanmar Oxford Clinical Research Unit (MOCRU) and the NGO Medical Action Myanmar (MAM) in Yangon, Myanmar.

“This significantly reduced malaria transmission and kept patients coming in to be screened for malaria, which is essential if we are to eliminate malaria in Myanmar,” explained Prof Smithuis.

The study did a retrospective analysis of over half a million malaria rapid diagnostic tests conducted between 2011 and 2016 by 1,335 CHWs supported by MAM in cooperation with the Myanmar Department of Health. Its results have important implications for Myanmar and other SE Asian countries racing to eliminate malaria.

“This study demonstrates that to eliminate malaria in hard to reach areas, CHWs networks should be offering malaria screening and treatment and basic health care,” said study contributor Mahidol and Oxford University Prof Sir Nicholas White. “Training health workers to just screen for malaria is not sustainable. These CHWs must offer a package for common health problems. This will sustain the popularity of the CHW services, benefit the accessibility of health services for the community and ensure that malaria is eliminated and then stays eliminated.”

“Many of the people we studied live in communities with no medical care of any kind other than local “quacks” and so remote that it could take 1-2 days of hard travel to reach them,” said Dr Alistair McLean, lead author. “Offering people in hard-to-reach communities a package of basic quality health services is essential to prevent malaria resurgence.”

The project was funded by The Global Fund to Fight AIDS, Tuberculosis and Malaria, the 3 Millennium Development Goal Fund, Planet Wheeler Foundation, Kadoorie Charitable Foundation, DAK Foundation, and The WellcomeTrust (UK).

MOCRU is the Myanmar Unit of the Mahidol Oxford Tropical Medicine Research Unit (MORU), a Wellcome-funded tropical health network based in Bangkok, Thailand.

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.